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Background: Previous observations suggest suboptimal ‘real world’ survival outcomes for advanced pancreatic adenocarcinoma.
We hypothesized that centralisation of advanced pancreatic adenocarcinoma management would improve chemotherapy
treatment and survival from the disease.
Methods: The data was prospectively collected on all cases of advanced pancreatic adenocarcinoma reviewed through
Clatterbridge Cancer Centre according to two groups; 1 October 2009–31st Dec 2010 (devolved care) or 1 January 2013–31 March
2014 (centralised care). Analysis included treatment received, 30-day chemotherapy mortality rate and overall survival (OS).
Results: More patients received chemotherapy with central care (67.0% (n¼ 115) vs 43.0% (n¼ 121); P¼ 2.2 10 4) with no
difference in 30-day mortality (20.8% vs 25%; P¼ 0.573) but reduced time to commencement of chemotherapy (18 vs 28 days,
P¼ 1.0 10 3). More patients received second-line chemotherapy with central care (23.4% vs 1.9%, P¼ 1.4 10 4), while OS was
significantly increased with central care (median: Five vs three months, HR 0.785, P¼ 0.045). Exploratory analysis suggested that
it was those with a poorer performance status, elderly or with metastatic disease who benefited the most from transition to
central care.
Conclusions: A centralised clinic model for advanced pancreatic cancer management resulted in prompt, safe and higher use of
chemotherapy compared with devolved care. This was associated with a modest survival benefit. Prospective studies are required
to validate the findings reported and the basis for improved survival with centralised care.
With 9400 new diagnoses in the UK in 2013 and a 5-year survival
rate of merely 3%, pancreas adenocarcinoma ranks among the
most lethal of malignancies (Cancer Research UK, 2016). The vast
majority of cases continued to be diagnosed at an advanced stage,
for which recent reports suggest no significant improvement in
survival over the past two decades (Sirri et al, 2016). Nevertheless,
modest benefits in terms of longer survival and improved quality of
life were demonstrated with palliative Gemcitabine chemotherapy
for advanced pancreatic adenocarcinoma nearly two decades ago
(Burris et al, 1997). More recently, longer median survival of
between 8 and 11 months has been demonstrated with combina-
tion chemotherapy compared with 6 months on single agent
Gemcitabine chemotherapy for metastatic disease (Garrido-Laguna
and Hidalgo, 2015).
A review of the survival data for more than 20 000 patients with
metastatic pancreatic adenocarcinoma in the US (1988–2008) by
Worni et al (2013) suggested that there was only marginal
improvement in the median survival from 2 to 3 months over
that period. It was observed that only a minority of patients
with advanced pancreatic adenocarcinoma received systemic
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chemotherapy, despite publication of the landmark trial, which
established the role of Gemcitabine palliative chemotherapy mid-
way through this period (Burris et al, 1997). The largest reported
UK regional retrospective study (2002–2005) on outcomes for
advanced pancreatic adenocarcinoma, also suggested a median
survival of 7.2 and 2.8 months, respectively, for patients with
locally advanced and metastatic disease (Mukherjee et al, 2008).
This would suggest inadequate translation of the modest
chemotherapy benefit from clinical trials to the ‘real-world’ patient
population. While patients accrued to clinical trials may be fitter,
the explanation for the discrepancy between trial and ‘real-world’
survival outcomes is uncertain. However, advanced pancreatic
adenocarcinoma is known to be associated with significant
morbidity and a poor prognosis. This introduces the necessity
for optimal supportive care and complex judgement in the
utilisation of chemotherapy treatment. Consequently, the relative
contribution of patient fitness outwith the clinical trial population
and practitioner attitude or limitations to suboptimal utilization of
chemotherapy in routine practice is uncertain.
Centralised care has been demonstrated to improve the
resection rate for early pancreatic adenocarcinoma (Gooiker
et al, 2014). Furthermore, centralised care has been shown to
reduce peri-operative mortality for patients with early pancreatic
(Neoptolemos et al, 1997) and oesophageal cancer (van Lanschot
et al, 2001). Increased surgeon specialization and peri-operative
supportive care are factors, which have been hypothesized to
contribute to the improved outcome for these malignancies treated
by complex surgical procedures. In this respect, we hypothesized
that centralisation of advanced pancreatic adenocarcinoma man-
agement could possibly improve supportive care, while improving
oncology specialist input, thus increasing chemotherapy utilisation
and potentially survival. Therefore, within the Merseyside and
Cheshire Cancer Network (North West England), we adopted a
transition from devolved to centralised pancreatic cancer manage-
ment during 2011 and 2012. We now try to determine the impact
of such modification in service delivery pattern by comparing
patient chemotherapy treatment trends and survival outcomes
astride the transition.
PATIENTS AND METHODS
This study was retrospective in nature with baseline characteristics
of patients, performance status and cause of death obtained from
patient records. However, date of referral, diagnosis, hospital site of
initial review, treatment records and the date of death had been
prospectively charted on a database by statisticians of the Clinical
Effectiveness team (CET). Ethical approval to review the database
and patient case records for the study was obtained from the
designated committee at the Centre. Patients with early pancreatic
adenocarcinoma were excluded from the study. Patients with
advanced pancreatic adenocarcinoma who fell into either of two
groups were studied:
Early group (E). Patients managed between 1 October 2009 and
31 December 2010.
Late group (L). Patients managed between 1 January 2013 and 31
March 2014.
Patients in Group E were managed prior to, while patients in
Group L were managed subsequent to, the centralisation of
pancreatic adenocarcinoma management in Clatterbridge Cancer
Centre. The groups were selected to cover similar intervals of time
astride the transition to centralised care but prior to the
introduction of Gemcitabine/Nab-Paclitaxel chemotherapy for
the malignancy in our centre. Patients in group E could be seen
by 5 different oncologists in any of five clinics distributed
throughout the Mereyside and Cheshire region. These devolved
clinics accommodated mostly patients with non-hepato-pancrea-
tobiliary (non-HPB) malignancies. In contrast, patients in Group L
were seen by two oncologists in two clinics dedicated to the
management of HPB malignancies in two main hospitals. Liaison
with HPB specialist nurses was available to the oncologists in
Group E as required. In contrast, one HPB Specialist Nurse was
regularly present for each of the clinics in Group L, while liaison
with other HPB specialist nurses was available as required. Ad-hoc
pathways for referral to dieticians, palliative care and other HPB
medical specialists was available to both groups as required, but
more direct referral pathways for such supportive care measures
was set up for the clinics in Group L.
The data on demographics, smoking history, past medical
history, histological diagnosis, cancer stage (locally advanced or
metastatic), performance status, date and clinic of initial appoint-
ment at CCC, treatment received (one or two lines), date of death
and cause of death were obtained. Smoking history was
dichotomized (non-smoker vs current/ex-smoker), while the
existence of a known diagnosis of diabetes mellitus or otherwise
was noted from the past medical history. The histological diagnosis
was recorded on the CET database but cross-checked with
pathology results, while cancer stage was determined from
radiology reports, which were updated by regional pancreatic
cancer multi-disciplinary team (MDT) review. WHO performance
status was that recorded at the time of review for commencement
of chemotherapy for those who received such treatment or at the
time of initial review in clinic for those who did not receive
chemotherapy. Patients who did not receive chemotherapy were
generally referred for community palliative care support and
discharged from the oncology clinic. Given historical 12-month
survival rates of o30% for advanced pancreatic adenocarcinoma,
the database was frozen for survival analysis on 30 September 2015,
permitting sufficient follow-up to calculate 12-month survival for
all patients and enough events to compare survival between both
groups in the study. Thirty-day mortality on chemotherapy was
taken as an interval of 30 days or less between the date of the last
dose of chemotherapy was received and the date of death.
Furthermore, overall survival was taken as the interval between
the date of the first visit to a CCC clinic and the date of death. We
tested for any differences between groups in demographics,
baseline characteristics, diagnosis of diabetes mellitus, type of
treatment received and 30-day mortality on chemotherapy by w2
analysis. Overall survival was computed by the Kaplan–Meier
technique with log-rank analysis. Statistical analysis was performed
by CET Statisticians CI and HW utilizing SPSS analytic software
(version 20.0, IBM, New York, NY, USA).
RESULTS
Baseline and treatment characteristics of patients. The baseline
characteristics of patients in early (E) and late (L) groups (are
displayed in Table 1A). In summary, similar numbers of patients
referred from the regional MDT were managed for advanced
pancreatic adenocarcinoma in both groups. There was no
significant difference in the age and gender distribution of both
the groups. However, there was significantly higher prevalence of
diabetes mellitus in Group L. In addition, increased prevalence of
metastatic disease in group L approached significance. Of note is
that a significantly higher proportion of patients received
chemotherapy in Group L. Further analysis in the metastatic
subset of patients suggested that chemotherapy treatment was
received by 36.1% (n¼ 72) in Group E and 63.4% (n¼ 82) in
Group L. We also compared the time to commencement of
chemotherapy after initial review between both groups and
observed a reduced time to commencement of chemotherapy in
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group L (E: mean¼ 28 days, 95% CI¼ 21–34; L: mean¼ 18 days,
95% CI¼ 15–22; P¼ 0.001). Therefore, patients treated in central
clinics had increased likelihood of commencing chemotherapy and
did so earlier than in the devolved clinics.
Overall survival with chemotherapy treatment. Progressive
cancer was the most commonly documented cause of death for
patient in both groups (91.7% (Group E] vs 82.8% [Group L)). To
determine if there was any difference in overall survival between
both groups, we compared survival between Groups E and L and
observed significantly increased survival for patients in Group L
(Figure 1A). As there was a higher proportion of patients with
metastatic disease in group L and the prognosis of metastatic
disease is worse (Bilimoria et al, 2007), we combined Groups E and
L, then determined if there was a difference in overall survival
between patients with locally advanced (LA) and metastatic (M)
disease (Figure 1B). We observed significantly increased survival
for patients with locally advanced compared with metastatic
disease. We then compared overall survival for patients with LA or
metastatic disease between groups E and L. There was no
difference in overall survival between groups E and L for LA
disease (data not shown). In contrast, longer survival was observed
for patients with metastatic disease in Group L (Figure 1C).
Therefore, there was a 36% improvement in overall survival for the
subgroup of patients with metastatic disease treated in centralised
clinics.
To assess survival with chemotherapy treatment in both groups,
survival was compared between patients who received chemother-
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Figure 1. Displays overall survival curves for patients with advanced pancreatic adenocarcinoma. (A) There was improved survival (HR: 0.785;
P¼0.045) for Group L (green; n¼ 115) compared with Group E (blue; n¼ 121). The median overall survival (and 12-month survival) were: 5 months
(14.8%) for Group L compared with 3 months (11.6%) for Group E. (B) Combining Groups E and L showed improved survival (HR: 0.637;
P¼4.1910 4) for LA (n¼82) compared with metastatic disease (n¼ 154). The median overall survival (and 12-month survival) was 7 months
(17.1%) for patients with LA compared with 3 months (11.0%) for patients with metastatic disease. (C) For the patients with metastatic disease,
there was improved survival (HR: 0.641; P¼ 0.002) for Group L (green; n¼82) compared with Group E (blue; n¼72). The median overall survival
(and 12-month survival) was 4 months (13.4%) for patients in Group L compared with 3 months (8.3%) for patients in Group E.
Table 1A. Baseline characteristics of patients with advanced pancreatic adenocarcinoma
Group Patients, n Median age
(range)
Male, n (%) DM, n (%) Smoking,
n (%)
Met, n (%) Systemic
Rx, n (%)
Rx site CCC or
RLUH, n (%)
E 121 68.45 (41-88) 64 (52.9) 22 (18.2) 24 (19.8) 72 (59.5) 52 (43) 81 (66.9)
L 115 69.48 (40-91) 52 (44.8) 38 (32.2) 15 (13.0) 82 (71.3) 77 (67.0) 89 (77.4)
Diff, P-value (E vs L) NA 0.615 0.192 0.013 0.16 0.057 0.000216 0.074
Abbreviations: CCC¼Clatterbridge Cancer Centre; Diff¼difference; DM¼diabetes mellitus; Met¼metastatic; n¼ number; NA¼not available; RLUH¼Royal Liverpool University Hospital,
Rx¼ treatment. Some demographic characteristics and treatment details of patients in the early (E) and late (L) groups are displayed.
Table 1B. Chemotherapy treatment for patients with advanced pancreatic adenocarcinoma
First-line, n (%) Second-line, n (%)
Chemotherapy
Group
Any regimen,
n (%)
G or G-based,
n (%)
FOLFIRINOX,
n (%)
G-Trials,
n (%)
Any regimen,
n (%)
G or
G-based,
n (%)
F or
F-based,
n (%)
30-day Mortality
(First or Second-line),
n (%)
Any regimen, n (%)
E 52 29(55.8) 0 23(44.2) 1(1.9) 0 1(1.9) 13(25)
L 77 58(75.3) 9(11.5) 10(13) 18(23.4) 10(13.0) 8(10.4) 16(20.8)
Diff, P-value (E vs L) 0.000216 0.02 0.011 0.000066 0.00014 0.279 0.573
Abbreviations: Diff¼difference; F¼ fluoropyrimidine; G¼Gemcitabine; n¼number. The details of chemotherapy treatment in the first- and second-line setting for patients in the early (E) and
late (L) groups are displayed. Note that 6 cases of 30-day mortality in Group L were in patients on second-line chemotherapy (31.6% of patients on second-line chemotherapy in group L). The
single patient on second-line chemotherapy in Group E did not die within 30-days of completing chemotherapy.
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apy and those who did not in either group (Figures 2A and B).
Patients who received chemotherapy had significantly improved
survival in both groups with similar median overall survival.
Therefore, despite the increased proportion of patients treated with
chemotherapy in Group L, survival was similar for patients treated
with chemotherapy between centralised and devolved clinics.
Chemotherapy treatment received by patients. Analysis of
chemotherapy regimens received by patients in Groups E and L
is displayed in Table 1B: A Gemcitabine-containing regimen was
the most common regimen received in the first-line setting in
either group. More patients participated in clinical trials (based on
Gemcitabine regimens) in Group E, while FOLFIRINOX che-
motherapy (as a first-line regimen) was only available to patients in
Group L. Significantly more patients received second-line che-
motherapy in Group L compared with Group E (23.4% (n¼ 18) vs
1.9% (n¼ 1); P¼ 1.4 10 4). Therefore, patients were more likely
to receive second-line chemotherapy in the centralised clinics.
Thirty-day mortality and patient survival on chemotherapy.
Thirty-day mortality on chemotherapy was compared between
Groups E and L (Table 1B). There was no significant difference in
30-day mortality between both groups (E¼ 25% vs L¼ 20.8%,
P¼ 0.573). Furthermore, with the assumption of proportional
hazards of death for a median survival of 2 months, 30-day
mortality for patients who did not receive chemotherapy would
be B25%.
Overall survival by first-line chemotherapy regimen received is
displayed in Figure 3A. Median overall survival was 8 months for
FOLFIRINOX (n¼ 9), 7 months for Gemcitabine (n¼ 87) and 9
months for Gemcitabine trials (n¼ 33). With patients on
Gemcitabine (off trials) as reference, there was improved survival
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Figure 2. Displays survival curves for patients with advanced pancreatic adenocarcinoma with or without chemotherapy treatment. (A) Improved
survival (HR: 0.307; P¼ o1 10 4) with chemotherapy (green; n¼ 52) compared with no chemotherapy treatment (blue; n¼69) in Group E. The
median overall survival (and 12-month survival) was as follows: 7 months (23.1%) with chemotherapy compared with 2 months (2.9%) without
chemotherapy. (B) Improved survival (HR: 0.229; P¼o1 10 4) with chemotherapy (green; n¼77) compared with no chemotherapy treatment
(blue; n¼38) in Group L. The median overall survival (and 12-month survival) was as follows: 7 months with chemotherapy (22.1%) compared with 2
months (0%) without chemotherapy.
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Figure 3. Displays overall survival curves for patients with advanced pancreatic adenocarcinoma who received chemotherapy. (A) Survival for
patients who received different first-line chemotherapy regimens for advanced pancreatic adenocarcinoma; (Gemcitabine—green (n¼87),
Gemcitabine trials—grey (n¼33) and FOLFIRINOX—blue (n¼9)). The median overall survival (and 12-month survival) with the regimens were as
follows: 7 months–Gemcitabine (17.2%); 9 months—Gemcitabine trials (33.3%); and 8 months—FOLFIRIONOX (33.3%). Patients on Gemcitabine
trials had significantly improved survival compared with Gemcitabine off trials (P ¼ 0.02). In contrast, there was no significant difference in survival
between those who received Gemcitabine off-trials and those who received FOLFIRINOX treatment (P¼0.168). (B) Survival for patients who
received second-line chemotherapy. The median overall survival was 11 months with a 12-month survival of 42.1% (n¼19). (C) Survival for patients
from commencement of second-line chemotherapy. The median overall survival was 5 months with no 12-month survivor (n¼ 19).
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for patients who received Gemcitabine on trials but not with
FOLFIRINOX treatment (Figure 3A). Twelve-month survival was
33.3% for FOLFIRINOX, 17.2% for Gemcitabine and 33.3% for
Gemcitabine trials. Overall survival for the patients who received
second-line chemotherapy is displayed in Figure 3B. Median
overall survival for such patients (from time of diagnosis) was 11
months, with 42.1% alive at 12 months. In contrast, median overall
survival from the time of commencement of second-line
chemotherapy was 5 months (Figure 3C).
Exploratory analysis of chemotherapy treatment by age. To
determine if there was an age bias in selection of patients for
chemotherapy, we analysed treatment in Groups E and L by age-
group, comparing patientsp70 years of age with those470 years
of age. Significantly less patients 470 years of age were treated
with chemotherapy in Group E (470: 24.5% (n¼ 53) vs p70:
57.4% (n¼ 48); P¼ 3.0 10 4—Table 2A). We then compared
chemotherapy treatment between patients up to and those 470
years of age in Group L. There was no significant difference in
chemotherapy treatment by age in Group L (Table 2A). As there
was no significant age bias in selection for chemotherapy in Group
L, we compared survival between those up to or 470 years of age
(Figure 4A), no significant difference in overall survival was
observed. Similarly, no significant difference in 30-day mortality
was observed (Table 2A). Finally, to determine the survival impact
of increased utilization of chemotherapy in the older population of
patients, we compared survival between groups E and L for
patients 470 years of age (Figure 4B). Increased overall survival
was observed for patients470 years in Group L compared with E.
Therefore, older patients (470) were at least twice as likely to
receive chemotherapy with centralised care. This translated to
increased survival similar to that of younger patients who received
chemotherapy.
Exploratory analysis of chemotherapy treatment by performance
status in older patients. To determine if poorer performance
status (42) in patients 470 years of age explains reduced
utilization of chemotherapy treatment in Group E, we analysed
patient distribution for performance status by age in Groups E and
L (Table 2A). A significantly reduced proportion was estimated to
be of PS 0–2 among patients470 compared with patients up to 70
years of age in Group E (p70: 80.9% (n¼ 68) vs 470: 56.6%
(n¼ 53); P¼ 0.004). In contrast, while there was a trend towards
higher performance status in general in Group L, there was no
significant difference in the proportion of patients estimated to be
of PS 0–2 by age in Group L (p70: 91.0% (n¼ 67) vs470: 83.3%
(n¼ 48); P¼ 0.21). Therefore, there was a trend to a poorer
performance status estimate for older patients with devolved care
associated with non-reception of chemotherapy.
Exploratory analysis of chemotherapy treatment and survival by
performance status in the entire population. To determine if
there was any difference in chemotherapy treatment between
Groups E and L at a given performance status estimate, we
summarized chemotherapy treatment by performances status in
both groups (Table 2B). There was no significant difference in the
proportion of patients who received chemotherapy at a given
performance status. However, the proportion of ‘fit’ patients (PS 0
and 1) in Group E was 36.9% (n¼ 121) compared with 61.8%
(n¼ 115) in Group L. Therefore, while reception of chemotherapy
treatment was not significantly different at a given PS in both
groups, patients in Group E were generally estimated to be of lower
performance status than those in Group L.
Given the difference in PS distribution between both groups, we
then compared overall survival for ‘fit’ patients (PS0/1—Figure 4C)
and for relatively ‘frail’ patients (PS2—Figure 4D) between Groups
E and L. Overall survival was similar for PS0/1 patients between
Groups E and L. In contrast, patients of PS2 had significantly
improved survival in Group L compared with Group E (HR: 0.594,
P¼ 0.022). Furthermore, 12-month survival for the PS2 population
was 13.3% for Group L while there were no 12-month survivors for
Group E. Therefore, similar survival to devolved care was observed
for the proportionately larger PS0/1 population with centralised
care. In contrast, longer survival was observed for the PS2
population with centralised care. Given the lead-time bias to
initial clinic review in Group L, for the small but frailer PS2
population, we compared time to commencement of chemother-
apy and survival between Groups E and L (from the time of
commencement of chemotherapy). Improved survival for PS2
patients from the time of commencement of chemotherapy was
observed in Group L (HR: 0.41, P¼ 0.012—Supplementary
Figure 1).
Exploratory analysis of chemotherapy regimen by age and
performance status. Patients who received FOLFIRINOX (med-
ian age¼ 53.2; n¼ 9) were younger than those who received
Gemcitabine (median age¼ 68.8; n¼ 87) or participated in
Table 2A. Chemotherapy treatment by age group for patients with advanced pancreatic adenocarcinoma
Group Age subgroup n (% of Group)
PS 0–2, n (% of
age subgroup)
Chemotherapy
treatment, n (% of age
subgroup)
30-day mortality on
treatment, n (% of age
subgroup)
E (n¼ 121) p70 68(56.2) 55(80.9) 39(57.4) 9(23.1%)
470 53(43.8) 30(56.6) 13(24.5) 4(30.8%)
Diff. (P-value) NA 0.004 0.000296 0.316
L (n¼115) p70 67(58.3) 61(91.0) 49(73.1) 10(15%)
470 48(41.4) 40(83.3) 28(58.3) 6(12.5%)
Diff. (P-value) NA 0.212 0.096 0.711
Abbreviations: Diff¼difference; n¼ number; NA¼not available; PS¼WHO performance status. Chemotherapy treatment by age groups (younger:p70 or older :470) in the early (E) and late (L)
groups is displayed with the associated 30-day mortality. The proportion of patients estimated to be of PS0-2 for each age group is also displayed.
Table 2B. Chemotherapy treatment by performance status in
patients with advanced pancreatic adenocarcinoma
Group PS0 PS1 PS2 PS3 PS4
E
n¼121 (%) 3(2.5) 42(34.7) 40(33.0) 34(28.1) 2(1.6)
Chemotherapy Rx (n¼ 52),
n (% at given PS)
3(100) 32(76.2) 17(42.5) 0(0) 0(0)
L
n¼115 (%) 11(9.6) 60(52.2) 30(26.1) 14(12.2) 0
Chemotherapy Rx (n¼ 77),
n (% at given PS)
11(100) 50(83.3) 15(50) 1(7.1) 0(0)
Diff, P-value NA 0.371 0.533 0.115 NA
Abbreviations: Diff¼Difference; n¼ number; NA¼ not available; PS¼WHO performance
status; Rx¼ treatment. Chemotherapy treatment by performance status for patients in the
early (E) and late (L) groups is displayed.
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Gemcitabine trials (median age¼ 66.9; n¼ 33). Furthermore,
patients who received FOLFIRINOX were entirely of PS 0 and 1,
while patients who received Gemcitabine were mostly of PS 1 and 2
(Supplementary Table 1). There was no significant difference in
30-day mortality between the regimens. Therefore, there was a
trend to FOLFIRIONOX been given to younger, fitter patients.
Notably, all those who received FOLFIRINOX also received
second-line chemotherapy, while only a minority (11.5%) of those
who received Gemcitabine received second-line chemotherapy.
DISCUSSION
The crucial findings in this study on advanced pancreatic
adenocarcinoma management are that transition to centralised
care tended to increase performance status overall (possibly by
improved supportive care), associated with increased utilization of
systemic chemotherapy and longer survival. Noteworthy is that the
proportion of patient treated with chemotherapy prior to
centralisation of care in our centre and the median survival for
patients with metastatic disease prior to centralisation were very
similar to that of the previously reported UK retrospective study
(Mukherjee et al, 2008). The increment in survival with centralised
care for this poor prognosis malignancy was modest, but
reassuringly, the increased utilisation of chemotherapy with
centralisation was achieved without delayed clinical review or a
rise in the proportion of deaths within 30 days of chemotherapy
treatment. Unfortunately, we did not have the serial PS data
collected to determine if earlier initial clinic review or improved
supportive care in centralised clinics explained improved overall PS
in central clinics. However, the improved detection of diabetes with
centralised care may reflect improved screening for purposes such
as a supportive care measure. Furthermore, there was no objective
way to correlate quality of life with the clinic journey times and
survival differences observed in this study.
Notably, older patients, less fit patients (PS2) and those with
metastatic disease who instinctively would be more likely to be
recommended to the convenience of devolved care, benefitted the
most from centralised care. However, increased utilisation of
supportive input such as from the HPB-specialist nurses/dieticians/
palliative care and more rapid access to HPB-specialist medical
support through the centralised clinics would be the most plausible
explanation. Furthermore, given the subjectivity of PS assessment,
underestimation of patient fitness for initiation and continuation
of chemotherapy in the devolved care setting is possible.
OS by age in patients treated with chemotherapy
 in group L OS for patients with PS 0–1 in group E vs L
OS for patients with PS 2 in group E vs L
OS for patients older than 70 years
 of age in group E vs L
1.0
0.8
Cu
m
 s
ur
vi
va
l
Cu
m
 s
ur
vi
va
l
Cu
m
 s
ur
vi
va
l
Cu
m
 s
ur
vi
va
l
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
0.00 6.00 12.00
Months
Months Months
Months
18.00
0.00 6.00 12.00 18.00 0.00 6.00 12.00 18.00
0.00 6.00 12.00 18.00
Age group Group
Group
E
E-Censored
L-Censored
L
E
E-Censored
L-Censored
L
Group
E
E-Censored
L-Censored
L
70
70
>70-Censored
70-Censored
A
B D
C
Figure 4. Displays overall survival curves for sub-populations with advanced pancreatic adenocarcinoma. (A) There was no significant difference
in survival (P¼0.606) for patients treated with chemotherapy in Group L stratified by age (blue:470 years; n¼ 28) and (greenp 70 years; n¼49).
The median overall survival (and 12- month survival) was as follows: 7 months (17.9%) for older patients compared with 8 months (24.5%) for
younger patients. (B) There was improved survival (HR: 0.698; P¼0.047) for older patients (470 years of age) in Group L (green: n¼48) compared
with Group E (blue: n¼ 53). The median overall survival (and 12-month survival) was as follows: 4 months (10.4%) for Group L compared with 3
months (7.5%) for Group E. (C) There was no significant difference in survival (P¼0.324) for all patients of PS0 and 1 between Group E (blue;
n¼45) and Group L (green; n¼ 71). The median overall survival (and 12-month survival) was as follows: 8 months for Group E (28.9%) compared
with 6 months for Group L (18.3%). (D) There was improved survival for patients of PS2 (HR: 0.594; P¼ 0.022) in Group L (green; n¼ 30) compared
with Group E (blue; n¼ 40). The median overall survival (and 12-month survival) was 4 months (13.3%) for patients in Group L compared with 3
months (0%) for patients in Group E.
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Particularly, when patients with advanced pancreatic adenocarci-
noma are seen in joint clinics dominated by patients with less
morbid malignancies. However, with respect to fitness, the
assessment of PS at the time of initial review (for untreated
patients) but the time of commencement of chemotherapy (for
treated patients) may have introduced bias. This would have
favoured patients who received centralised care, given the greater
proportion of patients who received chemotherapy in that group.
Nevertheless, the improved fitness and longer overall survival with
the centralised care approach would be desirable, irrespective of a
less nihilistic chemotherapy fitness assessment or frailer popula-
tions benefitting from a more proactive management pathway
being the explanation. However, distinction between these two
possibilities would be crucial to guide service design, particularly as
regards to the possibility of improving outcomes with better
supportive care in the devolved care setting. Similar to observations
with devolved care in this study (on advanced disease), a
retrospective study in the US observed overall less treatment for
older patients with early pancreatic adenocarcinoma (Amin et al,
2013).
While 30-day mortality on chemotherapy may have appeared
nominally high at 20–25%, the mortality was not significantly
different with centralisation and estimated not to be higher than
that for advanced pancreatic cancer patients off chemotherapy.
Patients treated with first-line Gemcitabine achieved median and
12-month survival comparable to patients treated with Gemcita-
bine on the control arm of the largest of the most recent first-line
clinical trials (von Hoff et al, 2013). Therefore, given that495% of
our patients on chemotherapy were on first-line Gemcitabine
regimens, this would suggest safe translation of the modest benefit
from previous first-line Gemcitabine trials to the treated ‘real-
world’ patient population in this study. While there was no
significant difference in survival for the PS0/1 population between
centralised and devolved clinics, longer survival for the ‘relatively
frail PS2 sub-set’ in centralised clinics may reflect increased
willingness to persist with systemic treatment in the less fit PS2
population in conjunction with better supportive care. The fact
that first-line trials were open throughout the period of devolved
care covered by this study, but only for part of the period covered
by centralised care, probably explains the increased recruitment to
first-line trials with devolved care.
The median overall survival of 5 months on second-line
chemotherapy compares favourably with recent fluoropyrimi-
dine-based second-line clinical trials (Pelzer et al, 2011; Oettle et al,
2014). In the central clinics, utilization of second-line chemother-
apy was nominally higher than the UK average of 15% (Smyth
et al, 2015). However, definitive clinical trial evidence of the benefit
of second-line chemotherapy emerged during the period of
transition from devolved to centralised care in this study. While
increased utilization of second-line chemotherapy and the
introduction of FOLFIRINOX with centralised care are potential
confounding factors in survival analysis here, some observations
would argue against their significance. The patients on FOLFIR-
INOX who comprised half of the populations that received second-
line chemotherapy in central clinics had no discernible survival
benefit.
The observation of comparable overall survival between
FOLFIRINOX and Gemcitabine treatment was possibly due to
median overall survival for our patients on FOLFIRINOX at 8
months being inferior to 11 months in the Conroy study (Conroy
et al, 2011). This was despite all our patients on FOLFIRINOX
receiving second-line Gemcitabine compared with B50% of those
on the Conroy study. However, given its recent introduction as at
that point in time and concerns about regimen toxicity, the
FOLFIRINOX-treated population appeared very highly selected
(comprising only 9 patients) and treatment was given without the
5-FU bolus. We cannot exclude the possibility that efficacy of the
FOLFIRIONOX regimen may have been compromised by omis-
sion of the 5-FU bolus. The only published trial of equivalent
efficacy of an attenuated FOLFIRIONX regimen to date, modified
the regimen in a different way but retained the 5-FU bolus
component. However, it reported that efficacy was similar despite
the modification (Stein et al, 2016). Furthermore, the young
population treated may have different disease biology and thus be
unrepresentative of typical survival outcomes with the regimen.
These possibilities require further evaluation. Survival for patients
on first-line Gemcitabine trials was longer than that for
Gemcitabine off-trial in this study. However, there was no survival
benefit on the intervention arm of the first-line trial, which ran for
most of the period of the study (Middleton et al, 2014), while the
results of the second trial are yet to be published. The longer
survival on trials may just reflect better overall care on clinical trial
protocols, which has previously been reported to be associated with
improved survival (Stead et al, 2011).
Our study has several limitations. The populations compared
were sequential rather than in parallel, meaning that improve-
ments, in general, such as in medical/oncology care, introduction
of Acute Oncology teams/patient management pathways could
have improved outcome in Group L. Furthermore, there were also
differences in chemotherapy regimen utilisation with centralised
care. The inadvertent difference in managing oncologists between
devolved and centralised care is also another potential confounder.
Consequently, the contribution of any or a combination of these to
survival differences is uncertain.
In conclusion, following transition to a centralised clinic model
in a tertiary cancer centre, we show safely increased utilization of
chemotherapy with a modest increase in overall survival for
patients with advanced pancreatic adenocarcinoma. Additionally,
we show that survival with first and second line chemotherapy was
similar to observations in clinical trials except for the limited
number of patients treated with FOLFIRIONOX. Counter-
intuitively, the benefits of centralised care were greatest for older
patients, those with metastatic disease and less fit patients. Further
prospective studies are required to validate the findings reported
from this exploratory study, to facilitate harnessing the modest but
increasing benefit of treatment for this poor prognostic malig-
nancy. However, to inform service design, such studies will need to
be appropriately designed to make the distinction between
inadequate resourcing for supportive care and nihilism in the
devolved care setting.
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